Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Avelumab with M1774 for the Treatment of Patients with ARID1A-Mutated Recurrent Endometrial Cancer who have Received Prior Immunotherapy

Trial Status: active

This phase II trial tests how well avelumab in combination with M1774 work together for treating patients with ARID1A-mutated endometrial cancer that has come back (recurrent) after receiving prior immunotherapy. Avelumab is a drug that binds to a protein called PD-L1 on tumor cells to block its ability to bind to other proteins found on T cells of the immune system. This blocking can help the immune system kill tumor cells. M1774 is a drug called an ATR-inhibitor, which prevents the growth of tumor cells by limiting their ability to repair damaged deoxyribonucleic acid (DNA). Giving avelumab and MI774 together may be safe, tolerable, and/or effective in treating patients with ARID1A-mutated recurrent endometrial cancer who have received prior immunotherapy.